SHENGDA BIO-PHARM(SH:603079)2025-01-20 09:00Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for 2024 to be between 26 million and 36 million CNY, marking a turnaround from a loss in the previous year[3]. - The net profit excluding non-recurring gains and losses is projected to be between 18 million and 26 million CNY for 2024[3]. - In the same period last year, the net profit attributable to shareholders was a loss of 54.06 million CNY, and the net profit excluding non-recurring gains and losses was a loss of 62.22 million CNY[5]. Performance Improvement Factors - The company achieved a significant improvement in performance due to refined management and technological enhancements, leading to cost reduction and efficiency gains[7]. - The sales structure of the company's products has been optimized compared to the same period last year, with increased revenue from high-value products such as pharmaceutical-grade vitamins and clean label products[7]. - The company emphasizes a differentiated competition strategy and has intensified market development efforts for clean label products[7]. Performance Forecast Reliability - There are no significant uncertain factors that could impact the performance forecast[8]. - The performance forecast data has not been audited by a registered accountant and is based on preliminary calculations by the company's finance department[9].